Generated: December 13, 2017
DrugPatentWatch Database Preview
Details for Patent: 5,618,913
« Back to Dashboard
Summary for Patent: 5,618,913
|Title:|| Insulin analogues|
|Abstract:||Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.|
|Inventor(s):|| Brange; Jens J. V. (Klampenborg, DK), Norris; Kjeld (Hellerup, DK), Hansen; Mogens T. (Lynge, DK) |
|Assignee:|| Novo Nordisk A/S (Bagsvaerd, DK) |
Patent Claim Types:|
see list of patent claims
|Compound; Formulation; |
No matches for this query
Foreign Priority and PCT Information for Patent: 5,618,913
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|Denmark||3956/85||Aug 30, 1985|
|Denmark||4677/85||Oct 14, 1985|
International Patent Family for Patent: 5,618,913
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.